Bristol Sprycel Cardiovascular Issues Not Enough To Prevent Accelerated Approval
This article was originally published in Pharmaceutical Approvals Monthly
QT prolongation appears to have been one of the primary safety considerations during FDA’s review of Bristol-Myers Squibb’s leukemia treatment Sprycel (dasatinib), review documents suggest.
You may also be interested in...
FDA’s decision to grant Pfizer’s Sutent a broad renal cell carcinoma claim suggests a consensus among reviewers that partial responses may be predictive of clinical benefit in RCC.
Redeeming a priority review voucher obtained by developing a drug for a tropical disease will cost companies $6.1 million in fiscal 2011